Results 51 to 60 of about 10,900 (261)

Molecular Evolution of Respiratory Syncytial Virus Fusion Gene, Canada, 2006–2010

Emerging Infectious Diseases, 2012
To assess molecular evolution of the respiratory syncytial virus (RSV) fusion gene, we analyzed RSV-positive specimens from 123 children in Canada who did or did not receive RSV immunoprophylaxis (palivizumab) during 2006–2010.
Jesse Papenburg, Julie Carbonneau, Marie-Ève Hamelin, Sandra Isabel, Xavier Bouhy, Najwa Ohoumanne, Pierre Déry, Bosco A. Paes, Jacques Corbeil, Michel G. Bergeron, Gaston De Serres, Guy Boivin   +11 more
doaj   +1 more source

Incidence of viral respiratory infections in a prospective cohort of outpatient and hospitalized children aged ≤5 years and its associated cost in Buenos Aires, Argentina [PDF]

, 2015
Background: Although information about the incidence of viral respiratory illnesses and their associated cost can help health officials explore the value of interventions, data are limited from middle-income countries.
Azziz Baumgartner, Eduardo, Carballal, Guadalupe, Durand, Lizette O., Echavarría, Marcela Silvia, Ekstrom, Jorge, Marcone, Débora Natalia, Vidaurreta, Santiago Manuel   +6 more
core   +1 more source

Bronchiolitis: an update on management and prophylaxis. [PDF]

, 2019
Bronchiolitis is an acute respiratory illness that is the leading cause of hospitalization in young children less than 2 years of age in the UK. Respiratory syncytial virus is the most common virus associated with bronchiolitis and has the highest ...
Bergroth E, Bont L, Brooks CG, Chen JJ, DeVincenzo JP, Donlan M, Farley R, Fernandes RM, Florin TA, Franklin D, Gadomski AM, Hanna S, Hartling L, Higgins D, Jaberolansar N, Jat KR, Karron RA, Kepreotes E, Li A, Liet JM, Liu F, Mayfield S, Mooney K, Murray J, Mussman GM, Neuzil KM., Oakley E, Ramilo O, Régnier SA, Shi T, Simões EAF, Sáez-Llorens X, The IMpact-RSV Study Group, Thompson M, Ventre K, Wegzyn C, Yi H, Zhang L, Zhang L   +38 more
core   +1 more source

Respiratory-syncytial virus immunoprophylaxis on asthma symptoms development in prematurity with bronchopulmonary dysplasia

Journal of Allergy and Clinical Immunology: Global, 2023
Background: Infants with respiratory-syncytial virus bronchiolitis hospitalization are more likely to develop wheezing and subsequent asthma. Reportedly, palivizumab prophylaxis effectively prevents respiratory-syncytial virus hospitalization in high ...
Li-Ching Fang, MD, Jen-Yu Wang, MD, Hsin-Hui Yu, MD, PhD, Li-Chieh Wang, MD, PhD, Bor-Luen Chiang, MD, PhD   +4 more
doaj   +1 more source

Likelihood reweighting methods to reduce potential bias in noninferiority trials which rely on historical data to make inference

, 2013
It is generally believed that bias is minimized in well-controlled randomized clinical trials. However, bias can arise in active controlled noninferiority trials because the inference relies on a previously estimated effect size obtained from a ...
Chu, Jianxiong, Nie, Lei, Rubin, Daniel, Zhang, Zhiwei   +3 more
core   +1 more source

Post-translational modifications and glycoprofiling of palivizumab by UHPLC–RPLC/HILIC and mass spectrometry

Journal of Proteins and Proteomics, 2022
Viral infections are progressively becoming a global health burden, as witnessed in the ongoing COVID-19 pandemic. Respiratory Syncytial Virus (RSV) is another highly contagious negative-sense RNA virus that causes lower respiratory tract infections and ...
K. Sran, Yogita Sharma, Tejinder Kaur, A. Rao   +3 more
semanticscholar   +1 more source

Cost-utility analysis of palivizumab in Italy: results from a simulation model in the prophylaxis of respiratory syncytial virus infection (RSV) among high-risk preterm infants

Italian Journal of Pediatrics, 2009
Introduction The aim of this study was to assess the cost-utility of palivizumab versus no prophylaxis in the prevention of respiratory syncytial virus infection among high-risk preterm infants.
Ravasio Roberto, Chirico Gaetano, Sbarigia Urbano   +2 more
doaj   +1 more source

Expert consensus on palivizumab use for respiratory syncytial virus in developed countries.

Paediatric Respiratory Reviews, 2020
Respiratory syncytial virus (RSV) infection is a leading cause of hospitalisation in early childhood and palivizumab is the only licensed intervention for prevention.
M. Luna, P. Manzoni, B. Paes, E. Baraldi, V. Cossey, A. Kugelman, R. Chawla, A. Dotta, R. Rodríguez Fernández, B. Resch, X. Carbonell-Estrany   +10 more
semanticscholar   +1 more source

Emerging drugs for respiratory syncytial virus infection [PDF]

, 2009
Although respiratory syncytial virus (RSV) was discovered > 40 years ago, treatment remains largely supportive. There are no safe and effective vaccines or specific treatments other than prophylaxis with passive antibody therapy (palivizumab).
Olszewska, W, Openshaw, P
core   +1 more source

Palivizumab Use in the NICU: 1999-2020.

Pediatrics, 2022
OBJECTIVE To examine the relationship between changes in American Academy of Pediatrics (AAP) guidance and palivizumab use for infants admitted to the NICU.
R. Clark, V. Tolia, K. Ahmad
semanticscholar   +1 more source